Enzyme and Reactive Oxygen Species–Responsive Dual-Drug Delivery Nanocomplex for Tumor Chemo-Photodynamic Therapy

References

• DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643–8653. doi:10.1158/0008-5472.CAN-07-6611
   PubMed Web of Science ®Google Scholar
• Sudhakar A. History of cancer, ancient and modern treatment methods. J Cancer Sci Ther. 2009;1(2):1–4. doi:10.4172/1948-5956.100000e2
   PubMedGoogle Scholar
• Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol. 2019;12(1):134. doi:10.1186/s13045-019-0818-2
   PubMed Web of Science ®Google Scholar
• Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009;7(1):99–108. doi:10.6004/jnccn.2009.0009
   PubMed Web of Science ®Google Scholar
• Lehar J, Krueger AS, Avery W, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009;27(7):659–666. doi:10.1038/nbt.1549
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang M, Zhou L, et al. Dual drug delivery and sequential release by amphiphilic janus nanoparticles for liver cancer theranostics. Biomaterials. 2018;181:113–125. doi:10.1016/j.biomaterials.2018.07.060
   PubMed Web of Science ®Google Scholar
• Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov. 2005;4(1):71–78. doi:10.1038/nrd1609
   PubMed Web of Science ®Google Scholar
• Fu X, Shi Y, Qi T, et al. Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting. Signal Transduct Target Ther. 2020;5(1):262. doi:10.1038/s41392-020-00342-0
   PubMed Web of Science ®Google Scholar
• Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–38043. doi:10.18632/oncotarget.16723
   PubMed Web of Science ®Google Scholar
• Rougier P, Mitry E. Review of the role of cpt-11 in the treatment of colorectal cancer. Clin Colorectal Cancer. 2001;1(2):87–94. doi:10.3816/CCC.2001.n.008
   PubMedGoogle Scholar
• Goetz MP, Erlichman C, Windebank AJ, et al. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol. 2003;21(20):3761–3769. doi:10.1200/JCO.2003.01.238
   PubMed Web of Science ®Google Scholar
• Alsaab HO, Alghamdi MS, Alotaibi AS, et al. Progress in clinical trials of photodynamic therapy for solid tumors and the role of nanomedicine. Cancers. 2020;12:10. doi:10.3390/cancers12102793
   Web of Science ®Google Scholar
• Song M, Liu T, Shi C, Zhang X, Chen X. Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward m1-like phenotype and attenuating tumor hypoxia. ACS Nano. 2016;10(1):633–647. doi:10.1021/acsnano.5b06779
   PubMed Web of Science ®Google Scholar
• Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5(4):496–504. doi:10.1021/mp800049w
   PubMed Web of Science ®Google Scholar
• Wang H, Zhao Y, Wu Y, et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy peg-plga copolymer nanoparticles. Biomaterials. 2011;32(32):8281–8290. doi:10.1016/j.biomaterials.2011.07.032
   PubMed Web of Science ®Google Scholar
• Khdair A, Chen D, Patil Y, et al. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J Control Release. 2010;141(2):137–144. doi:10.1016/j.jconrel.2009.09.004
   PubMed Web of Science ®Google Scholar
• Fan L, Li F, Zhang H, et al. Co-delivery of pdtc and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials. 2010;31(21):5634–5642. doi:10.1016/j.biomaterials.2010.03.066
   PubMed Web of Science ®Google Scholar
• Wiradharma N, Tong YW, Yang YY. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials. 2009;30(17):3100–3109. doi:10.1016/j.biomaterials.2009.03.006
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao S, Ye WH, Yoon HS, Yang YY. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater. 2006;5(10):791–796. doi:10.1038/nmat1737
   PubMed Web of Science ®Google Scholar
• Ma Q, Zhao Y, Guan Q, et al. Amphiphilic block polymer-based self-assembly of high payload nanoparticles for efficient combinatorial chemo-photodynamic therapy. Drug Deliv. 2020;27(1):1656–1666. doi:10.1080/10717544.2020.1850921
   PubMed Web of Science ®Google Scholar
• Li ZL, Cai H, Li ZQ, et al. A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-pd-l1 antibody. Bioact Mater. 2023;21:299–312. doi:10.1016/j.bioactmat.2022.08.028
   PubMed Web of Science ®Google Scholar
• Xiao XY, Cai H, Huang QR, et al. Polymeric dual-modal imaging nanoprobe with two-photon aggregation-induced emission for fluorescence imaging and gadolinium-chelation for magnetic resonance imaging. Bioact Mater. 2023;19:538–549. doi:10.1016/j.bioactmat.2022.04.026
   PubMed Web of Science ®Google Scholar
• Cai H, Tan P, Chen XT, et al. Stimuli-sensitive linear-dendritic block copolymer-drug prodrug as a nanoplatform for tumor combination therapy. Adv Mater. 2022;34(8):2108049. doi:10.1002/adma.202108049
   Web of Science ®Google Scholar
• Zheng XL, Pan DY, Zhu GN, et al. A dendritic polymer-based nanosystem mediates drug penetration and irreversible endoplasmic reticulum stresses in tumor via neighboring effect. Adv Mater. 2022;34(20):2201200. doi:10.1002/adma.202201200
   Web of Science ®Google Scholar
• Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003. doi:10.1038/nmat3776
   PubMed Web of Science ®Google Scholar
• Li D, Ma Y, Du J, et al. Tumor acidity/nir controlled interaction of transformable nanoparticle with biological systems for cancer therapy. Nano Lett. 2017;17(5):2871–2878. doi:10.1021/acs.nanolett.6b05396
   PubMed Web of Science ®Google Scholar
• Qiu M, Wang D, Liang W, et al. Novel concept of the smart nir-light-controlled drug release of black phosphorus nanostructure for cancer therapy. Proc Natl Acad Sci USA. 2018;115(3):501–506. doi:10.1073/pnas.1714421115
   PubMed Web of Science ®Google Scholar
• Fan RR, Chen CL, Hou H, et al. Tumor acidity and near-infrared light responsive dual drug delivery polydopamine-based nanoparticles for chemo-photothermal therapy. Adv Funct Mater. 2021;31(18):2009733. doi:10.1002/adfm.202009733
   Web of Science ®Google Scholar
• Saravanakumar G, Kim J, Kim WJ. Reactive-oxygen-species-responsive drug delivery systems: promises and challenges. Adv Sci. 2017;4(1):1600124. doi:10.1002/advs.201600124
   Web of Science ®Google Scholar
• van der Meel R, Sulheim E, Shi Y, et al. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14(11):1007–1017. doi:10.1038/s41565-019-0567-y
   PubMed Web of Science ®Google Scholar
• Wang J, Sun X, Mao W, et al. Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy. Adv Mater. 2013;25(27):3670–3676. doi:10.1002/adma.201300929
   PubMed Web of Science ®Google Scholar
• Sun CY, Zhang BB, Zhou JY. Light-activated drug release from a hyaluronic acid targeted nanoconjugate for cancer therapy. J Mater Chem B. 2019;7(31):4843–4853. doi:10.1039/c9tb01115c
   PubMed Web of Science ®Google Scholar
• Zhang L, Gao S, Zhang F, et al. Activatable hyaluronic acid nanoparticle as a theranostic agent for optical/photoacoustic image-guided photothermal therapy. ACS Nano. 2014;8(12):12250–12258. doi:10.1021/nn506130t
   PubMed Web of Science ®Google Scholar
• Wu J. The enhanced permeability and retention (epr) effect: the significance of the concept and methods to enhance its application. J Pers Med. 2021;11:8. doi:10.3390/jpm11080771
   Web of Science ®Google Scholar
• Park JH, Cho HJ, Yoon HY, et al. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery. J Control Release. 2014;174:98–108. doi:10.1016/j.jconrel.2013.11.016
   PubMed Web of Science ®Google Scholar
• Gao S, Wang G, Qin Z, et al. Oxygen-generating hybrid nanoparticles to enhance fluorescent/photoacoustic/ultrasound imaging guided tumor photodynamic therapy. Biomaterials. 2017;112:324–335. doi:10.1016/j.biomaterials.2016.10.030
   PubMed Web of Science ®Google Scholar
• Tan JX, Wang XY, Li HY, et al. Hyal1 overexpression is correlated with the malignant behavior of human breast cancer. Int J Cancer. 2011;128(6):1303–1315. doi:10.1002/ijc.25460
   PubMed Web of Science ®Google Scholar
• Choi KY, Chung H, Min KH, et al. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials. 2010;31(1):106–114. doi:10.1016/j.biomaterials.2009.09.030
   PubMed Web of Science ®Google Scholar
• Kalyanasundaram K, Thomas JK. Environmental effects on vibronic band intensities in pyrene monomer fluorescence and their application in studies of micellar systems. J Am Chem Soc. 1977;99(7):2039–2044. doi:10.1021/ja00449a004
   Web of Science ®Google Scholar
• Li J, Huo M, Wang J, et al. Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials. 2012;33(7):2310–2320. doi:10.1016/j.biomaterials.2011.11.022
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Cerwinka WH, Isoyama T, Lokeshwar BL. Hyal1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res. 2005;65(17):7782–7789. doi:10.1158/0008-5472.CAN-05-1022
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Chanmee T, Itano N. Hyaluronan: metabolism and function. Biomolecules. 2020;10:11. doi:10.3390/biom10111525
   Web of Science ®Google Scholar
• Cowman MK, Lee HG, Schwertfeger KL, McCarthy JB, Turley EA. The content and size of hyaluronan in biological fluids and tissues. Front Immunol. 2015;6:261. doi:10.3389/fimmu.2015.00261
   PubMed Web of Science ®Google Scholar
• Tavianatou AG, Caon I, Franchi M, et al. Hyaluronan: molecular size-dependent signaling and biological functions in inflammation and cancer. FEBS J. 2019;286(15):2883–2908. doi:10.1111/febs.14777
   PubMed Web of Science ®Google Scholar
• Zhu L, Zhao Y, Liu T, et al. Inhibition of NADPH oxidase-ros signal using hyaluronic acid nanoparticles for overcoming radioresistance in cancer therapy. ACS Nano. 2022;16(11):18708–18728. doi:10.1021/acsnano.2c07440
   PubMed Web of Science ®Google Scholar
• Stern R, Kogan G, Jedrzejas MJ, Soltes L. The many ways to cleave hyaluronan. Biotechnol Adv. 2007;25(6):537–557. doi:10.1016/j.biotechadv.2007.07.001
   PubMed Web of Science ®Google Scholar
• Franzmann EJ, Schroeder GL, Goodwin WJ, et al. Expression of tumor markers hyaluronic acid and hyaluronidase (hyal1) in head and neck tumors. Int J Cancer. 2003;106(3):438–445. doi:10.1002/ijc.11252
   PubMed Web of Science ®Google Scholar
• Kolliopoulos C, Bounias D, Bouga H, et al. Hyaluronidases and their inhibitors in the serum of colorectal carcinoma patients. J Pharmaceut Biomed. 2013;83:299–304. doi:10.1016/j.jpba.2013.05.037
   PubMed Web of Science ®Google Scholar
• Kramer MW, Escudero DO, Lokeshwar SD, et al. Association of hyaluronic acid family members (has1, has2, and hyal-1) with bladder cancer diagnosis and prognosis. Cancer. 2011;117(6):1197–1209. doi:10.1002/cncr.25565
   PubMed Web of Science ®Google Scholar
• McAtee CO, Barycki JJ, Simpson MA. Emerging roles for hyaluronidase in cancer metastasis and therapy. Adv Cancer Res. 2014;123:1–34. doi:10.1016/B978-0-12-800092-2.00001-0
   PubMed Web of Science ®Google Scholar
• Lokeshwar VB, Rubinowicz D, Schroeder GL, et al. Stromal and epithelial expression of tumor markers hyaluronic acid and hyal1 hyaluronidase in prostate cancer. J Biol Chem. 2001;276(15):11922–11932. doi:10.1074/jbc.M008432200
   PubMed Web of Science ®Google Scholar
• Jung H. Hyaluronidase: an overview of its properties, applications, and side effects. Arch Plast Surg. 2020;47(4):297–300. doi:10.5999/aps.2020.00752
   PubMedGoogle Scholar
• Tzircotis G, Thorne RF, Isacke CM. Chemotaxis towards hyaluronan is dependent on cd44 expression and modulated by cell type variation in cd44-hyaluronan binding. J Cell Sci. 2005;118(Pt21):5119–5128. doi:10.1242/jcs.02629
   PubMedGoogle Scholar
• Snezhkina AV, Kudryavtseva AV, Kardymon OL, et al. Ros generation and antioxidant defense systems in normal and malignant cells. Oxid Med Cell Longev. 2019;2019:1–17. doi:10.1155/2019/6175804
   Web of Science ®Google Scholar